ANTEOTECH LTD — Director's Dealing 2017

Sep 12, 2017

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Anteo Diagnostics Limited ABN 75 070 028 625

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Rolf Sickman
Date of last notice	2 February 2016

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and indirect interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Indirect holding held by Fronta Consultants NV which is a related party of Mr Sickman
Date of change	1stSeptember 2017
No. of securities held prior to change	4,664,800 fully paid ordinary shares held directly and indirectly as follows: Rolf Sickman 1,000,533 shares Fronta Consultants NV3,664,267shares
Class	Fully paid ordinary shares
Number acquired	4,704,866 fully paid ordinary shares
Number disposed	nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$81,005.09
No. of securities held after change	9,369,666 fully paid ordinary shares held directly and indirectly as follows: Rolf Sickman: 2,009,660 shares Fronta Consultants NV7,360,006 shares

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Nature of change Shares issued in accordance with the Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in share purchase agreement between Aneto buy-back Diagnostics Limited and the Vendors of DIAsource Immunoassays SA.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed above traded during a+closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011